233 related articles for article (PubMed ID: 29735794)
1. The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids.
Gottlieb A; Bechmann L; Canbay A
Ann Hepatol; 2018; 17(3):340-341. PubMed ID: 29735794
[TBL] [Abstract][Full Text] [Related]
2. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
3. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
Amacher DE
Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
[TBL] [Abstract][Full Text] [Related]
4. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
[TBL] [Abstract][Full Text] [Related]
5. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
6. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
[TBL] [Abstract][Full Text] [Related]
7. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
[TBL] [Abstract][Full Text] [Related]
8. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment.
Zhu L; Baker RD; Zhu R; Baker SS
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):3-5. PubMed ID: 29697548
[TBL] [Abstract][Full Text] [Related]
9. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
[TBL] [Abstract][Full Text] [Related]
10. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.
Ferslew BC; Xie G; Johnston CK; Su M; Stewart PW; Jia W; Brouwer KL; Barritt AS
Dig Dis Sci; 2015 Nov; 60(11):3318-28. PubMed ID: 26138654
[TBL] [Abstract][Full Text] [Related]
11. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
[TBL] [Abstract][Full Text] [Related]
12. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
13. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
[TBL] [Abstract][Full Text] [Related]
14. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
17. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
[TBL] [Abstract][Full Text] [Related]
18. The Gut Microbiota and Nonalcoholic Fatty Liver Disease.
Quigley EM; Monsour HP
Semin Liver Dis; 2015 Aug; 35(3):262-9. PubMed ID: 26378643
[TBL] [Abstract][Full Text] [Related]
19. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
20. Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis.
Chen J; Zheng M; Liu J; Luo Y; Yang W; Yang J; Liu J; Zhou J; Xu C; Zhao F; Su M; Zang S; Shi J;
Obesity (Silver Spring); 2019 Dec; 27(12):2055-2066. PubMed ID: 31657148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]